Revela raises £411,000 pre-seed round to advance AI-powered diagnosis for endometriosis
Endometriosis affects millions of women, often taking years to diagnose
UK femtech start-up Revela has raised a £411,000 pre-seed round to further develop its AI-powered ultrasound technology for diagnosing endometriosis and other women’s health conditions.
The round brings together PXN Ventures North of England through its PraeSeed programme, alongside angel investors from Sixth Wave Ventures, Mint Ventures, Alma Angels and Leeds Angels.
Revela, co-founded by Molly Jowsey and Tom Willshare, is building machine-learning tools designed to detect endometriosis non-invasively via ultrasound analysis. The company says the technology could help shorten diagnostic delays that currently average more than eight years, despite the condition affecting an estimated one in ten women.
Steve Kelly, co-founder and partner at Sixth Wave Ventures, said:
“At Sixth Wave Ventures, we invest in and support truly pioneering startups and the exceptional founders behind them through our Sixth Wave angel group. Revela is a fantastic example — a company tackling a major global women’s health challenge with innovation, scientific rigor, and real-world impact.”
Gillian Fleming, Co-Founder and Managing Director of Mint Ventures, added:
“At Mint Ventures we back women led purpose driven companies who are building products the world has been missing. We believe Revela is poised to make a significant difference to women’s health, and we’re excited to be part of their journey.”
PXN Ventures supported the team through its six-week PraeSeed programme prior to investment, providing education, workshops and cohort-based support. Revela said the programme allowed investors and the founding team to “really get to know each other” ahead of the raise.
In a statement, the company emphasised that the diagnostic tool is being developed in collaboration with clinicians and women living with endometriosis to ensure clinical relevance and patient-centred design. Revela argues that earlier and more accessible diagnosis could reduce reliance on invasive surgical procedures, shorten the path to treatment, and improve the experience of patients navigating the health system.
The new funding will be used to expand development data, progress technical build, and deepen collaborations ahead of a future product launch. The company said it aims to accelerate work on a “game-changing” diagnostic tool, positioning the technology as a potential alternative to current approaches that often require invasive laparoscopy.
Revela thanked its investors for their financial and strategic support, noting that several angel groups involved had already been advising the company prior to the round. “Our backers aren’t just funding us; they’re true believers in women’s health innovation,” the team said.